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Fetuins are among the major plasma proteins, yet their biological role has remained elusive. Here 
we report the molecular cloning of rat fetuin and the sequence analysis of a full-length clone, RF619 
of 1456 bp with an open reading frame of 1056 bp encoding 352 amino acid residues. The coding 
part of RF619 was identical with the cDNA sequence of the natural inhibitor of the insulin receptor 
tyrosine kinase from rat (pp63) except for four substitutions and a single base insertion causing 
divergence of the predicted protein sequences. Partial amino acid sequences of rat plasma fetuin were 
in agreement with the predictions based on the RF619 cDNA. Purified rat fetuin inhibited the insulin 
receptor tyrosine kinase in vitro. Therefore, we conclude that RF619 and pp63 cDNA encode the 
same protein, i.e. authentic rat fetuin which is a functional tyrosine kinase inhibitor. 
Fetuins are among the most abundant proteins of fetal 
plasma. The bovine protein, first identified and named fetuin 
by Pedersen (1944), is present in fetal plasma at concentrations 
reaching 5 g/l. The corresponding human protein, a2-HS gly- 
coprotein (Schultze et al., 1962) was isolated from adult hu- 
man plasma (Schmid and Burgi, 1961) and later recognized 
as the human homologue of bovine fetuin (Christie et al., 
1987). Prefetuins are secretory proteins of approximately 360 
amino acid residues. They are post-translationally modified 
by proteolytic cleavage into a two-chain form (Kellermann et 
al., 1989), by N- and 0-glycosylation (Edge et al., 1987; Yet 
et al., 1988) and/or by sulfation (Hortinet al., 1986). Structural 
and evolutionary studies revealed that fetuins possess a tripar- 
tite structure, i.e. two N-terminally located domains (Dl, D2) 
of cystatin-like structure, followed by a unique COOH-termi- 
nal domain (D3) unrelated to other mammalian proteins 
(Elzanowski et al., 1988). 
Although much is known about the structure and biosyn- 
thesis of the fetuins, the central question of their biological 
role(s) has remained elusive. Bovine fetuin is widely used as 
an additive to cell culture media because it promotes cell 
growth (Puck et al., 1968). Accumulation of Q-HS glyco- 
protein in the non-collagenous bone matrix has suggested a 
role of the protein in enchondral ossification (Trifftt et al., 
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1976; Yang et al., 1991). Furthermore, functional roles for 
mammalian fetuins have been proposed in the regulation of 
lipogenesis (Cayatte et al., 1990), endocytosis (Lewis and 
Andrk, 1980), opsonization (van Oss et al., 1974) and inflam- 
mation (Daveau et al., 1990). Each of these functions, how- 
ever, applies to a species-specific fetuin, but none represents a 
universal role for the fetuins. 
Recently we demonstrated an unexpected sequence simi- 
larity between human Q-HS glycoprotein, bovine fetuin, and 
the natural inhibitor of the rat insulin receptor tyrosine kinase, 
pp63 (Haasemann et al., 1991). Overall sequence identity was 
56 - 60% (percentage residues in identical positions of the 
proteins), indicating that pp63 might represent a structurally 
related, but functionally distinct, protein of the rat, or the rat 
homologue of human and bovine fetuins (Haasemann et al., 
1991; Falquerho et al., 1991; Brown et al., 1991). 
Here we have set out to further define the structural and 
functional relationship between fetuins and pp63. Screening 
of a rat liver cDNA library with a cDNA probe derived from 
a human a2-HS glycoprotein cDNA resulted in the isolation 
of a full-length clone (RF619) encoding rat fetuin. The protein 
sequence predicted from the RF619 cDNA is similar to the 
protein sequence derived from clone pp63 except for the C- 
terminal region where the two sequences diverge. The results 
from direct amino acid sequence analyses of fetuin isolated 
from rat plasma were in agreement with the predictions from 
the RF619, but not from the pp63 cDNA. In vitro experiments 
demonstrated that purified rat fetuin significantly and repro- 
ducibly inhibits the tyrosine kinase activity associated with 
partially purified human insulin receptor. Therefore, we con- 
clude that clones RF619 and pp63 encode the same protein, 
i.e. authentic rat fetuin, a tyrosine kinase inhibitor. 
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EXPERIMENTAL PROCEDURES 
Rat fetuin cDNA clones 
A I. ZAP I1 cDNA library prepared from rat liver mRNA 
(Stratagene) was plated out at a density of 2 x lo4 plaque- 
forming units/90-mm dish. Out of 400000 independent re- 
combinants, five clones (RF619, RFlbl ,  RF6b1, RF6b2, 
RFI 5b2) were selected which strongly hybridized to a 1600- 
bp cDNA encoding human a2-HS glycoprotein (R. Vogel and 
W. Miiller-Esterl, unpublished results). This probe was 32P 
labeled, typically to a specific activity of 5 x 10' dpm/pg, using 
random primers (Feinberg and Vogelstein, 1983). The nitro- 
cellulose filters (Schleicher and Schuell) were washed in 
2 x NaCl/Cit (NaCl/Cit: 0.15 M sodium citrate, 0.15 M so- 
dium chloride, pH 7.0) and 0.1% SDS for l h at 55°C and 
autoradiographed. 
Hybridization techniques 
RNA from different rat organs were isolated according 
to the guanidine-isothiocyanate/CsCl method (Davis et al., 
1986). Rat genomic DNA for Southern-blot analysis was pur- 
chased from Clontech. Northern and Southern hybridizations 
were carried out as described (Sambrook et al., 1989). In 
both hybridization experiments, a poly(viny1idene difluoride) 
membrane (Millipore) was used. The probe was derived from 
a 1300-bp EcoRI fragment of clone RF619, and was 32P 
labeled using the random-primer technique. Final washes were 
in 0.1 x NaCl/Cit containing 0.1% SDS for 1 h at 65°C for 
Northern blots, and in NaCl/Cit containing 0.1% SDS for 
30 rnin at 65 "C for Southern blots. 
Sequencing strategy 
Plasmid and single-stranded DNA of the five 3, ZAP 11 
clones containing rat fetuin sequences were isolated by rescue 
excision according to the manufacturer's instructions 
(Stratagene). The complete nucleotide sequence of clone 
RF619 and the partial nucleotide sequences of clones RF1 bl,  
RF6b1, RF6b2 and RF15b2 were established by the chain- 
termination method (Sanger et al., 1977) using a T7 se- 
quencing kit (Pharmacia). 
Rat fetuin isolation 
The purification procedure for rat fetuin is based on the 
isolation scheme for plasma acid-stable trypsin inhibitors of 
the plasma (Albrecht et al., 1983). Heparinized rat plasma 
(194 ml) was mixed with 1 : 10 vol. 12 M perchloric acid. The 
mixture was incubated for 30 min at 4°C then centrifuged 
(20 rnin 4200 x g).  The supernatant was removed and adjusted 
to pH 7.8 (2 M KOH). After 14 h at 4"C, the resultant precipi- 
tate was removed by centrifugation (4200 x g, 20 min). To the 
supernatant (165 ml), 5 ml trypsin-Sepharose prepared from 
1.5 g BrCN-Sepharose (Pharmacia) and 30 mg N"-tosylphe- 
nylalaninechloromethane-treated bovine trypsin (Sigma) was 
added and the suspension was rotated end-over-end (1 h, 4 "C). 
The gel was transferred into a column and unbound protein 
was washed out with 25 ml equilibration buffer (0.05 M Tris, 
0.1 M KCI, pH 8.0). Bound proteins were eluted with 1 M 
KC1, pH 2.2 (HCI), and fractions of 0.5 ml were collected. 
Trypsin inhibitor activity was determined using N"-benzoyl-L- 
arginine-4-nitroanilide as the substrate. Fractions containing 
trypsin-inhibiting activity were pooled and subjected to re- 
versed-phase HPLC on a Hypersil WP-300 butyl column 
(4.6 mm x 250 mm). The mobile phase was composed of sol- 
vent A [0.1% (by vol.) trifluoroacetic acid in water] and sol- 
vent B [0.1 YO (by vol.) trifluoroacetic acid in acetonitrile]. The 
gradient consisted of five linear segments ranging over 22- 
40% B in A. The effluent was continuously monitored at 
216 nm. The solvent flow was 1 ml/min and fractions of 0.5 ml 
were collected. 
Amino acid sequence analysis 
Isolated proteins were reduced, alkylated with iodoacetic 
acid or 4-vinylpyridine and desalted on a PD-10 column 
(Pharmacia) with water/formic acid/2-propanol (5 : 4: 1, by 
vol.). For digestion with endoproteinase Lys-C (Boehringer 
Mannheim), polypeptides were incubated with 1-2% (by 
mass) enzyme in 25 mM Tris/HCl and 1 mM EDTA, pH 8.5, 
for 19 h at 37°C. Further separation of the modified peptides 
was accomplished by reversed-phase HPLC. Amino acid se- 
quences were determined with a gas-phase sequencer (Applied 
Biosystems, Model 477A) connected to an on-line HPLC 120A 
system for identification of the phenylthiohydantoin deriva- 
tives. Typically, 50 - 200 pmol peptide/run was applied. The 
repetitive yields of representative runs ranged over 89.1 - 
94.8Y". 
Receptor preparation 
Human placenta tissue (9 - 10 g) was homogenized in 
25 mM Hepes, pH 7.5 (homogenization buffer), including 
2.5 mM phenylmethylsulfonylfluoride, 1200 U/l aprotinin, 
10 mM benzamidine and 7500 U/l bacitracin using an 
Ultraturrax blender. The homogenate was centrifuged 
(150000 x g ,  20 min, 4°C). The supernatant was discarded and 
the pelleted material was treated (30min, 4°C) with 
homogenization buffer containing 1 O h  Triton X-100. Follow- 
ing centrifugation (200000 x g ,  50 min) to remove insoluble 
material, the supernatant was diluted fourfold with homog- 
enization buffer including 0.05% Triton X-100 (dilution 
buffer). The solubilized membranes were applied to a column 
of wheat-germ agglutinin agarose (2 ml) followed by extensive 
washing with dilution buffer. The bound material was eluted 
with 0.3 M N-acetylglucosamine dissolved in the same buffer. 
The protein concentration of the collected samples was deter- 
mined by a colorimetric assay (Bio-Rad). Fractions with the 
highest protein content were pooled and stored under liquid 
nitrogen. 
Substrate phosphorylation 
Partially purified insulin receptor protein (1.5 - 2 pg) was 
treated with insulin (1 pM) in the absence or presence of rat 
fetuin (1.8 - 1100 pM), human a2-HS glycoprotein, bovine 
fetuin, human L-kininogen or human His-rich glycoprotein 
(all at 50 pg/ml; 0.74- 1.1 nM) for 30 rnin at 22°C. This was 
followed by incubation (10 rnin 22°C) with 0.5 to 5.0 pM 
ATP supplemented with trace amounts of [y-32P]ATP (5 pCi; 
specific activity, 3000 Ci/mmol; NEN) in a final volume of 
30 $25 mM Hepes, pH 7.5, containing 0.05% Triton X-100, 
12 mM MgCI,, 12 mM MnC1, and 1 mM sodium vanadate. 
Substrate phosphorylation was initiated by adding 1 mM 
poly(Glu,Tyr) (4: 1, sodium salt). The reaction was stopped 
after 20 min by transferring the mixtures to Whatman 3 MM 
paper squares soaked with 20 mM sodium pyrophosphate in 
10% trichloroacetic acid. The filters were washed seven times 
in the same fixation agent and bound radioactivity was 
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quantified by liquid scintillation counting. The basal activity 
(395221 cpm . h-' . pg-') of the receptor tyrosine kinase was 
increased 3.5 & 0.3-fold by insulin; this stimulated state was 
arbitrarily ascribed 100% activity. 
Receptor binding studies 
Samples, each containing 2.5 pg partially purified receptor 
protein, were incubated with 50 mM Tris buffer, pH 7.5, con- 
taining 10 mM MgS04, 1% bovine serum albumin, 20000 
cpm '251-insulin (specific activity 2200 Ci/mmol, NEN) and 
decreasing concentrations (0.1 - 1000 nM) of unlabeled insu- 
lin, in the presence or absence of rat fetuin (24 pg/ml; 0.5 nM) 
for 45 min at 22°C (final volume, 125 pl). Separation of free 
and receptor-bound insulin was accomplished by dextran- 
coated charcoal. The amount of 251-insulin bound to the 
receptor was quantified in a y counter. 
Receptor autophosphorylation 
Partially purified receptor protein (3-3.5 pg) was incu- 
bated (22"C, 30 min) with insulin (1 pM) in the absence or 
presence of 30 pg/ml (0.67 nM) rat fetuin or 50 pg/ml 
(0.74 nM) human L-kininogen. This was followed by incu- 
bation at 22°C with 5 pM ATP supplemented with trace 
amounts of [y-32P]ATP (1OpCi) in 25mM Hepes, pH 7.5, 
containing 0.05% Triton X-100, 10 mM MnC12 and 1 m M  
sodium vanadate. The incubation was terminated by the ad- 
dition of SDS sample buffer, containing 100 mM dithio- 
threitol, and subsequent boiling for 25 min. The phosphopro- 
teins were separated by SDSjPAGE in a 7.5% polyacrylamide 
gel (Laemmli, 1970) and identified by autoradiography. j2P- 
labeled bands were cut from the gel and Cerenkov radiation 
was measured. 
RESULTS 
Molecular cloning of rat fetuin cDNA 
A cDNA probe was generated by random priming using 
a human c12-HS glycoprotein cDNA as the template. We 
screened a cDNA library constructed from rat liver mRNA in 
phage 1 ZAP I1 and identified multiple clones (approximately 
0.3 O/O of 400 000 independent recombinants) which specifically 
hybridized to the probe. Five of them (designated RF) were 
plaque-purified, and their inserted cDNA were characterized 
by sequence analysis using universal primers. Clone RF619 
comprised a full-length cDNA of approximately 1500 bp, 
whereas the other clones (RFlbl,  RF6b1, RF6b2, RF15b2) 
contained incomplete cDNA covering 800 - 1400 bp of the rat 
fetuin cDNA (not shown). Sequence analysis by the specific 
primer-directed strategy (Strauss et al., 1986) revealed that 
clone RF619 contains 1456 bp, including 31 bp of the 
untranslated 5' end, 1056 bp encoding the entire rat prefetuin 
molecule, and 369 bp of the 3' untranslated region, including 
the polyadenylation signal of AAT AAA, and a poly(A) tail 
of eight residues (Fig. 1). The open reading frame of clone 
RFhl9 translates into a protein of 352 amino acid residues 
(37939 Da) containing 14 cysteine residues, a potential signal 
peptide of 18 residues (including two cysteine residues), three 
potential N-glycosylation sites of the general structure Asn- 
Xaa-Thr/Ser and two dibasic cleavage sites of Arg-Lys/Arg. 
In a Northern-blot analysis, we used a randomly primed 
probe derived from the RF619 template to detect hybridizing 
message in total RNA from various rat tissues. These exper- 
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Fig. 1. The cDNA sequence for rat fetuin and its deduced amino acid 
sequence derived from clone RF619. The numbers below (above) the 
lines refer to the nucleotide (amino acid) sequence. The stop codon is 
marked by an asterisk, and the polyadenylation signal, AAT AAA, is 
underlined. The bold line above the protein sequence identifies the 
signal peptide (von Heijne, 1986). Portions of the protein sequence 
were verified by amino acid sequence analysis (upper thick lines). 
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iments indicated that the major site of biosynthesis of rat 
fetuin is the liver; a single species of mRNA of approximately 
1600 bp was found (not shown). RNA extracted from brain, 
lung, kidney, spleen and uterus failed to give a positive signal, 
even after prolonged exposure. Southern-blot analysis of rat 
genomic DNA digested by the restriction enzymes EcoR1, 
Hind111 or BarnHI in each case revealed a single fragment 
hybridizing to the RF619 probe (not shown). This indicates 
the existence of a single copy gene for fetuin present in the rat 
genome. 
Sequence comparison of RF619 and pp63 cDNA 
Comparison of the cDNA sequences of clones RF619 and 
pp63 (Auberger et al., 1989) revealed that the two sequences 
are almost identical in their core parts but diverge in their 
flanking regions. The 5’ end of the pp63 cDNA, containing a 
putative initiator codon AUG, is not present in clone RF619, 
whereas a second AUG codon, located 51 bp downstream of 
the putative pp63 initiator codon is found in both cDNA. The 
latter, but not the former, site is preceded by the sequence 
GCC, a prototypic sequence motif flanking the translation- 
initiation sites in eukaryotic mRNA (Kozak, 1989), and co- 
incides with the known translation-initiation sites of mam- 
malian fetuins (Haasemann et al., 1991). Moreover, the 5’ 
untranslated regions of the RF3 5b2 cDNA (not shown), ex- 
tending the RF619 sequence by 9 bp, diverges from the pp63 
cDNA, but is in complete agreement with the corresponding 
genomic sequence of pp63 (Falquerho et al., 1991), suggesting 
that the 5’ region of the pp63 cDNA is a cloning artifact. No 
differences between the two cDNA exist at the 3’ end, except 
that RF619 extends the pp63 cDNA by 32 bp including a 
poly(A) tail of eight residues. 
The sequences of the coding parts of RF619 and pp63 are 
congruent except for four substitutions at position 167 (G +C; 
Asp-His), position 257 (G-C; Glu+Gln) and positions 842/ 
843 (GC-CG; Ala+Arg; RF619 numbering). Furthermore, 
an extra G residue was assigned to position 1041 of the RF619 
sequence which is not present in the pp63 cDNA (Fig. 2). The 
presence of an extra G residue was confirmed on both strands 
of the RF619 cDNA and further established by the partial 
sequence analysis of clone RF6bl (not shown). Insertion of a 
single G residue results in a frame shift causing divergence of 
the C-terminal portions of the protein sequences predicted 
from the RF619 and pp63 cDNA (Fig.3). To resolve this 
discrepancy, partial amino acid sequences of rat fetuin were 
established. 
Isolation and characterization of rat fetuin 
Bovine fetuin is an effective inhibitor of bovine trypsin 
(Rohrlich and Rifkin, 1981). In a strategy exploiting the poten- 
tial trypsin-binding properties of the rat protein, we isolated 
fetuin from rat plasma applying affinity chromatography on 
trypsin - Sepharose4B. The purified protein had an apparent 
molecular mass of approximately 45 kDa, indicating that it 
might have undergone proteolytic cleavage (note that the ap- 
parent molecular masses of mammalian fetuins are approxi- 
mately of 50-60 kDa). Reductive cleavage of the disulfide 
bonds and separation of the released chains of rat fetuin led 
to the identification of two major fragments (RFI-3.1 and 
RFI-l), indicating that the rat fetuin had been isolated in a 
two-chain form. Edman degradation was employed to estab- 
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Fig. 2. Identification of an extra G residue at position 1041 of the RF619 
cDNA. The additional G nucleotidc is marked by an asterisk. The 
specified scquence (left) reads positions 1028- 1051 of the RF61Y 
sequence, corresponding to Ala-Gly-Ala-Ala-Gly-Pro-Val-Ala (posi- 
tions 333-340 of the prefetuin sequence). 
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Fig. 3. Light-chain portions of rat fetuin, pp63, human aZ-HS glyeo- 
protein and bovine fetuin. (A) Comparison of the protein sequences 
prcdicted from clones RF619 and pp63, and the sequencc of the ral 
fetuin light chain (RFI-I). The point of sequence divergence is marked 
by a solid triangle. Note that the C-terminal isoleucine residue was 
absent in the protein sequence of RFI-1, probably due to an exo- 
proteolytic activity. (B) Comparison of the C-terminal sequences of 
various mammalian fetuins corresponding to the light chain of human 
a2-HS glycoprotein. ra, rat fetuin (this work); human r2-HS glyco- 
protein (Lee et al., 1987); bo, bovine fetuin (Dziegielewska et a]., 
1990). Conserved amino acid residues are boxed. Numbers identify 
the relative positions (prefetuin sequences) of the first given residue. 
except for the rat light-chain sequence which starts at position 1. 
Identification of the rat fetuin heavy and light chains 
The sequence of RFI-3.1 coincides with the predicted N- 
terminus of rat fetuin (Fig. 1, residues 19-42); it is identical 
with the N-terminal sequence of nine residues, recently estab- 
lished for a rat bone matrix protein (Mizuno et al., 1991). 
RFI-1 matches a sequence located at the extreme C-terminus 
of rat fetuin, but not to any other known protein sequence 
from the rat. The RFI-1 sequence starts at a position adjacent 
to the N-terminal residue of the light chain of human at- 
HS glycoprotein (Fig. 1, residues 327 - 351). Therefore, we 
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conclude that RFI-1 represents the light chain and RFI-3.1 
the corresponding heavy chain of rat fetuin, and that the two 
chains are interconnected by disulfide bridging. 
Fragment RFI-1 of rat fetuin covers the C-terminal region 
diverging between the two predicted protein sequences of 
RF619 and pp63. The protein sequence of RFI-1 is in complete 
agreement with the amino acid sequence predicted from 
RF619, but not with the protein sequence deduced from clone 
pp63 (Fig. 3). Hence, the protein sequence data confirm the 
assignment of an extra G residue at position 1041 of the 
RF619 cDNA sequence. Furthermore, this sequence fits well 
with the sequence alignments of the mammalian fetuin family, 
whereas the corresponding sequence derived from clone pp63 
does not. 
4J.L Partial sequence analysis of the rat fetuin heavy chain 
To obtain further sequence data of the isolated protein, 
fragment RFI-3.1 was cleaved by endoproteinase Lys-C and 
the peptides were isolated by HPLC. Direct amino acid 
sequencing confirmed all the predictions based on the RF619 
cDNA (Fig. l) ,  including the assignment of Glu at position 
76 where Gln is predicted from the pp63 cDNA sequence. 
None of the sequenced fragments contained a (potential) N- 
glycosylation site, however a single fragment spanning resi- 
dues 249-268 contained a threonine at position 267 which 
probably carries an 0-linked carbohydrate side chain as has 
been found for the corresponding positions of the human and 
bovine fetuins. Note that sequence polymorphism occurred at 
position 51 where either His or Asp were present in protein 
derived from individual animals. 
In conclusion, our data strongly suggest that clones RF619 
and pp63 encode one and the same protein, i.e. rat fetuin, and 
that the inconsistencies observed between the two cDNA are 
most probably due to cloning artifacts and/or sequencing 
errors of the pp63 cDNA. 
Homology of rat fetuin with other mammalian fetuins 
Comparison of the rat fetuin sequence derived from clone 
RF619 with the known sequences of other mammalian fetuins 
disclosed extensive sequence identities dissipated over the en- 
tire polypeptide chains including the C-terminal regions (not 
shown). The sequence identities range over 56.3 - 59.6% (pro- 
tein level), and 72.5 - 74.9% (cDNA level). The typical tripar- 
tite structure of mammalian fetuins composed of two N-ter- 
minally located cystatin-like domains (Dl,  D2; Muller-Ester1 
et al., 1985; Elzanowski et al., 1988) and a single C-terminal 
domain (D3) unique to the fetuins (Kellermann et al., 1989; 
Rawlings et al., 1990) is also shared by rat fetuin. The N- 
terminal portion of D3 (residues 253 - 297) which is charac- 
terized by the abundance of proline in other mammalian 
fetuins, is also present in the rat protein (29% of the positions 
are occupied by Pro). Likewise, dibasic cleavage sites for pro- 
teolytic processing (Arg-Lys/Arg), acceptor sequences for N- 
glycosylation (Asn-Xaa-Thr/Ser) and recognition sites for 
phosphorykation by casein-like kinases (Ser/Thr-Xaa-Xaa- 
Asp; Kemp and Pearson, 1990) are found in positions shared 
with the other mammalian fetuins (not shown). 
Functional properties of rat fetuin 
Identification of pp63 as authentic rat fetuin raises the 
question whether this protein is an inhibitor of the insulin- 
receptor-associated tyrosine kinase, and, if so, whether this 
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Fig. 4. Inhibition of insulio-stimulated substrate phosphorylation by rat 
fetuin. Solubilized insulin receptor from human placenta was treated 
with 1 pM insulin in the presence of increasing concentrations of rat 
fetuin (1.8 - 1100 pM) and subsequently tested for tyrosine kinasc 
activity by determining the incorporation of [32P]phosphate into 
poly(Glu,Tyr). Bars indicate the percentage inhibition of substrate 
phosphorylation (no inhibition in the absence of fetuin). 
functional role is unique to the rat protein or common to all 
mammalian fetuins. To address this issue, we tested the effect 
of purified rat fetuin on the tyrosine kinase activity associated 
with the human insulin receptor. 
Inhibition of substrate phosphorylation 
The insulin receptor was partially purified from human 
placenta, and its tyrosine kinase activity was measured by 
the incorporation of [32P]phosphate into the copolymer 
poly(Glu,Tyr) in the presence or absence of rat fetuin. Sub- 
strate phosphorylation induced by insulin (1 pM) was inhibit- 
ed by rat fetuin in a concentration-dependent manner and 
ranged from less than 5% inhibition (1.8 pM fetuin present in 
the phosphorylation assay) to 67% inhibition, when the fetuin 
concentration was raised to 1.1 nM (Fig. 4). 
We also determined the inhibitory effect of other mam- 
malian fetuins, i.e. human a2-HS glycoprotein and bovine 
fetuin, and of structurally related proteins, i.e. human histi- 
dine-rich glycoprotein and human L-kininogen (Rawlings and 
Barrett, 1990). All proteins were applied at a concentration 
of 50 pg/ml (0.74- 1.1 nM). When insulin-induced substrate 
phosphorylation was attributed 100% on a relative scale, rat 
fetuin (1.1 nM) reduced this value to 33 11%, whereas the 
human and bovine homologues did not significantly inhibit 
the tyrosine kinase activity in three independent experiments 
(106 18% and 99 f 19%, respectively). The fetuin-related 
proteins L-kininogen and histidine-rich protein were also inef- 
fective in kinase inhibition (112 f 16% and 95 f 18%). 
Inhibition of insulin receptor autophosphorylation 
The autophosphorylation of the 95 kDa B subunit of the 
insulin receptor was monitored in the presence (0.67 nM) 
or absence of rat fetuin using [Y-~~PIATP and recorded by 
autoradiography. The basic autophosphorylation activity of 
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and function of the receptor proteins, surprisingly little infor- 
mation is available regarding their natural modulators, e.g. 
inhibitors (Coughlin et al., 1987). The recently isolated and 
characterized phosphoprotein pp63 typifies such a kinase in- 
hibitor (Auberger et al., 1989). 
Molecular cloning and direct amino acid sequence analysis 
of rat fetuin now demonstrates that pp63 structurally belongs 
to the large family of mammalian fetuins (Dziegielewska et 
al., 1983; Jones et al., 1988). Furthermore, functional analysis 
of the isolated rat protein proves that fetuin is an efficient 
inhibitor of the tyrosine kinase activity associated with the 
insulin receptor. The fact that rat fetuin (this work) and pp63 
(Auberger et al., 1989) were isolated by entirely different puri- 
fication procedures suggests that the kinase inhibitor activity 
is a genuine property of rat fetuin rather than the characteristic 
of copurifying protein(s) which escaped identification by se- 
quence analysis. Unlike rat fetuin, the homologues isolated 
from human and bovine plasma lack a significant inhibitor 
activity. This might be explained by the fact that only the 
phosphorylated form of pp63/fetuin is active in tyrosine kinase 
inhibition, whereas the partially dephosphorylated form 
prevalent in the plasma is 10-fold less active (Le Cam et al., 
1985; Auberger et al., 1989). Hence, the possibility remains 
that bovine and human fetuins were isolated from plasma in 
their dephosphorylated forms. 
Fetuins are among the major plasma proteins with concen- 
trations ranging over 0.4- 5.0 g/1 (Dziegielewska et al., 1980). 
Quantification of fetuin in normal rat plasma by radioimmu- 
noassay (Fink et al., unpublished results) revealed that the 
actual plasma concentration of the protein is at least two 
orders of magnitude higher than the previously published 
concentration of 2- 3 mg/l (Auberger et al., 1989). A regulat- 
ory mechanism such as reversible protein phosphorylation 
(Cohen, 1982) would provide an efficient molecular switch to 
modulate fetuin’s inhibitory activity. 
The demonstration of the structural and functional iden- 
tity of fetuin and pp63 has several major implications. First, 
the identification of one of the fetuins as a tyrosine kinase 
inhibitor might indicate that other members of this widely 
occurring protein family could serve the same function. Sec- 
ond, insulin-receptor-like molecules are known to play a cru- 
cial role during growth, development and differentiation. In- 
triguingly, the expression of the fetuins is most prominent 
during fetal development (Dziegielewska and Saunders, 1988), 
and fetuins have been localized in developing brain (Mrallgtird 
et al., 1984), embryonal cartilage (Lee et al., 1987) and ossify- 
ing tissue (Trifftt et al., 1976; Colclasure et al., 1988; Yang et 
al., 1991). The observed spatial and temporal distribution 
patterns of fetuins suggest an important role in the molecular 
control of growth and development which could be exerted 
through their inhibitor activity towards receptor kinases. The 
recent identification of a glycoprotein inhibiting the insulin 
receptor tyrosine kinase in a patient with non-insulin-depen- 
dent diabetes mellitus (Sbraccia et al., 1991) supports the 
conjecture that protein inhibitors might also play an im- 
portant role in the regulation of tyrosine kinase activity in 
adult life. Finally, the detailed knowledge of structural proper- 
ties of the fetuins will facilitate the elucidation of the molecular 
mechanisms underlying the inhibition of receptor-associated 
tyrosine kinases. 
Fig. 5. Effect of rat fetuin on insulin-induced receptor autophosphoryla- 
tion. Solubilized insulin receptor from human placenta was stimulated 
with 1 pM insulin in the absence (lane 2) or presence of 0.67 nM rat 
fetuin (lane 3) or 0.74 nM human L-kininogen (lane 4). and incubated 
with [y-32P]ATP. To measure unstimulated autophosphorylation, the 
receptor was incubated in the absence of insulin and fetuin (lane 1). 
Phosphoproteins were separated by SDSjPAGE in a 7.5% poly- 
acrylamide gel; the corresponding autoradiography is shown. 
the solubilized human insulin receptor (Fig. 5, lane 1) was 
stimulated 2.8-fold (100%) in the presence of 1 pM insulin 
(Fig. 5, lane 2). Simultaneous incubation of the receptor with 
insulin and rat fetuin reduced the insulin-induced autophos- 
phorylation by 33% (Fig. 5, lane 3; 1 .%fold stimulation). Incu- 
bation of the receptor with insulin and a fetuin-related protein, 
L-kininogen (0.74 nM) gave a 4.1-fold increase over the basic 
activity, signifying a stimulatory effect of this protein (Fig. 5 ,  
lane 4). Therefore, we conclude that rat fetuin is an in vitro 
inhibitor of the insulin-receptor-associated tyrosine kinase and 
this property is shared with the rat pp63 protein (Auberger et 
al., 1989). 
We incubated the solubilized insulin receptor with 0.01 
nM lZ5I- insulin and varying concentrations (0.1 -1000 nM) 
of the unlabeled hormone in the absence or presence of rat 
fetuin (0.5 nM) to test the possibility that fetuin and insulin 
compete for the same binding site of the insulin receptor CI 
subunit. A Scatchard plot analysis of the binding data revealed 
congruent displacement curves in the presence or absence of 
rat fetuin (not shown). We conclude that rat fetuin, like pp63 
(Auberger et al., 1989), is a modulator of the receptor-associ- 
ated tyrosine kinase activity operating at a region which is 
external to the ligand-binding site of the receptor. 
DISCUSSION 
Tyrosine kinase activity is associated with a large number 
of growth-hormone receptors, including the receptors for in- 
sulin, insulin-like growth factors, epidermal growth factors, 
platelet-derived growth factor and fibroblast growth factors. 
In addition, multiple oncogenes, e.g. c-src, c-neu, c-erB and c- 
kit,  represent receptor-like molecules which express tyrosine 
kinase activity (for review, cf. Ullrich and Schlessinger, 1990). 
While substantial knowledge has accumulated on the structure 
We are indebled to M. Arnhold for technical assistance, to S. 
Holz for secretarial help and to E. Haas for the preparation of the 
illustrations. This work was supported by grants-in-aid Mu 598/3-1 
(to W.M.E.) from the Deutsche Forschunk.sgernein.sc~iuft, H-5 (to 
529 
E.F.). 2-2 (to M.E.) and F-7 (to H.U.H.) from the 
Soridei:lorsc.hi,t/~~s~ereic/i 207 of the University of Munich and the 
 fond^ dc.r Clieniischen Itzdirstrie (to W.M.E.). 
REFERENCES 
Albrecht. G. J . .  Hochstrasser. K.  & Schonberger. 0. L. (1983) Hoppe- 
Auberger. P.. Falquerho. L.. Contreres. J .  O., Pages, G., Le Cam, G.. 
Brown. W. M.. Christie. D. L.. Dziegielewska. K. M. & Saunders, N. 
Cayatte. A. J.. Kumbla. L. & Subbiah. M. T.  R. (1990) J .  B i d .  Chenz. 
Christie. D. L.. Dziegielewska. K. M.. Hill. R. M. & Saunders. N. R .  
(1987) FEBS Lett. -714.45-49. 
Cohen. P. (1982) Nurure 296. 613-620. 
Colclasure. G. C.. Lloyd. W. S . ,  Lamkin. M.. Gonnerman. W.. 
Troxler. R. F.. Offiier. G. D.. Biirgi. W., Schmid. K. & Nimberg. 
R. B. (1988) J .  C h i .  Endoc~rii~ol. Merab. 66. 187- 192. 
Coughlin. J .  P.. Donahoe. P. K.. Budzik. G.  P. & MacLaughlin. D. 
T.  (1987) Mol. Cell. Ettdocrinol. 49. 75- 85. 
Daveau. M.. Davrinchc. C.. Djelassi. N.. Lcmetaycr, J.. Julen, N.. 
Hiron. M.. Arnaud. P. & Lebreton. J .  P. (1990) FEBS Lett. 273. 
Davis. L. G.. Dibner. M. D. & Battey. J. F. (1986) Basic riiethods iti 
t i io /ecu/ur  hiolog!.. Elsevier. New York. 
D7iegiele\vska. K .  M.. Evans, C. A. N., Fossan. G.. Lorscheider. F. 
1.. Malinowska. D. H.. Mdlgird.  K.. Reynolds, M. L., Saunders, 
N. R. & Wilkinson. S. (1980) J .  P/i.~siol. (L0nd.j 300. 441 -455. 
Dziegielewska. K.  M.. Bock. E.. Cornelis. M. E. P., M0llgh-d. K.. 
New. H. & Saunders. N. R. (1983) Conzp. Biochen?. Plipiol. 76A, 
Dziegiele\vska. K.  M. & Saunders, N. R. (1988) in Handbook qfhuiizan 
groii,r/i mid dei,elopiieritol biologj, (Meisami. E. & Timiras, P. S.. 
eds) pp. 169- 191. CRC Press. Boca Raton. 
Dziegielewska. K. M.. Brown. W. M.. Casey. S. J.. Christie. D. L.. 
Foreman. R. C.. Hill. R. M. & Saunders. N. R. (1990) J. B i d .  
Cherii. -765. 4354-4357. 
Edge. A. S. B. & Spiro. R. G. (1987) J. Biol. Cheni. 262, 16135- 
16141. 
Elzano\vski. A,. Barker. W. C., Hunt. L. T. & Seibel-Ross. E. (1988) 
Falquerho. L.. Patey. G.. Paquereau. L., Rossi, V., Lahuna, 0.. 
Szpirer. 1.. Szpirer. C.. Levan. G. & Le Cam. A. (1991) Gene 
Se.vler'5 2. Ph!~io l .  Cherii. 364. 1697 - 1702. 
Kossi. B. & Le Cam. A. ( 1989) Cell j8. 63 1 - 640. 
R. (1991) Cell. in the press. 
265. 5883 -5888. 
79-81. 
241 - 245. 
F€BS Lett. 227. 167 - 170. 
~ , 4 l l l 3 t . !  98. 209-216. 
Feinberg. A. P. & Vogelstein. B. (1983) A n d .  Biochenz. 132. 6-13. 
Haasemam. M.. Nauratil. P. & Miiller-Esterl. W. (1991) Biockem. J .  
-774. 899 - 902. 
Hortin. G.. Green. E. D., Baenziger. J .  U. & Strauss. A. W. (1986) 
Jones. S. E., Dziegiclewska. K. M.. Saunders, N.  R., Christie, D. L.. 
Kellermann. J.. Haupt. H., Auerswald. E. A. & Miiller-Esterl. W. 
Kemp. B. E. & Pcarson. R. B. (1990) Trends Bioclierii. Sci. 1.5, 342- 
Kozak. M. (1989) J .  Cell Biol. 108, 229-241. 
Laemmli. U. K.  (1970) Nuture227.680-685. 
Le Cam. A.. Magnaldo, I.. Le Cam, G. & Auberger. P .  ( 1  985) J .  Biol. 
Lee. C. C., Bowman, B. H. & Yang, F. (1987) Proc. A'ml Acutl. Sci. 
Lewis. J. G. & Andre, C. M. (1980) Irizmunology 39. 317-322. 
Mizuno. M., Farach-Carson, M.  C.,  Pinero, G. J.. Fujisawa, R.. 
Brunn. J. C., Seyer, J. M.. Bousfield, G. R., Mark. M. P. & Butler. 
W. T. (1991) Bone Miner. 13, 1-21. 
Mdlgard. K.. Reynolds. M. L., Jacobsen, M.. Dziegielew5ka. 
K.  M. & Saunders, N. R. (1984) J. . ~ m w J ' f O / .  13, 497 - 502. 
Miiller-Esterl. W., Fritz, H., Kellermann, J.,  Lottspeich, F.. 
Machleidt, W. &Turk, V. (1985) FEBS Lett. 191,221 -226. 
Pedersen, K .  0. (1944) Nature 154, 575. 
Puck. T. T.. Waldren. C. A. & Jones. C. (1968) Proc. Ncitl  Acud. Sci. 
Rawlings. N. D. & Barrett. A. J. (1990)J. Mo/. Evol. 30. 60-71. 
Rohrlich, S. T. & Rifkin. D. B. (1981) J .  Cell. Phj,siol. 10Y. 1 - 15. 
Sambrook, J. ,  Fritsch, E. F. & Maniatis, T, (1989) Moleuilw cloning, 
a laborutor~~manrtal. Cold Spring Harbor Laboratory. Cold Spring 
Harbor. New York. 
Sanger. F., Nicklen, S. & Coulson, A. R.  (1977) Proc. Nut/ Acad. Sci. 
Sbraccia, P.; Goodman, P. A., Maddux, B. A.. Wong, K. Y.. Chen. 
Y. D. I.. Reaven. G. M. & Goldfine. 1. D. (1991) Diuberes 40. 
Schmid. K. & Biirgi. W. (1961) Biochim. Biop/ij,s. A(,tcr 47. 440-453. 
Schultze. H. E.. Heide. K .  & Haupt. H. (1962) Nar~r~i~~i.s.sen.scli~~tet? 
Strauss. E. C.. Kobori, J. A.. Siu, G. &Hood. L. (1986) And. Biocl/et?i. 
Triffitt. J. T.. Gebauer. U., Ashton. B. A,, Owen, M. E. & Reynolds. 
Ullrich, A. & Schlessinger, J .  (1990) Cell 61. 203-212. 
Van Oss. C. J., Gillman. C. F.. Bronson, P. M. & Border, J .  R. (1974) 
Von Heijne. G. (1986) Nucleic Acids Res. 14. 4683 - 4690. 
Yang. F.. Schwartz. Z., Swain, L. D.,  Lee, C. C.. Bowman. B. H. & 
Yet, M. G.. Chin. C. C. Q. & Wold, F. (1988) J .  Bio/. C%etiz. 263. 
Biocheni. J .  235, 401 - 414. 
Sueirdz-Diaz, J .  & Szelke. M. (1988) F€BS Let t .  236.411 -414. 
(1989) J .  B i d .  Chem. 264, 14121 -14128. 
344. 
Chetiz. 260. 15 965 - 15 971. 
U S A  84.4403 -4407. 
USA 59. 192 - 199. 
USA 74, 5463 - 5467. 
295 - 299. 
49. 15. 
154. 353-360. 
J. J .  (1 976) Natrrre 262. 226 - 227. 
hnmunol. Cornnzun. 3, 329- 335. 
Boyan, B. D. (1991) Bone l N Y /  12. 7-15. 
11 - 1  17. 
Sote added in the proof. Upon reexamination of their sequence data. 
Le Cam et al. identified an additional G residue in position 1083 of 
the pp63 cDNA (corresponding to position 1041 of the RF619 cDNA 
sequence). The corrected sequence is available a t  the EMBL sequence 
data bank under accession number M29758. 
